e3banpc-742.jpg e3banph-408.jpg


  • Mar 18, 2024

    CDE Clears IND Application for Therapeutic Candidate Targeting ATTR

    The first in vivo gene editing drug using lipid nanoparticle to receive clinical approval in China

    Read More

  • Mar 13, 2024

    YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

    March 19th to 21st, 2024, at the Westin Miyako Kyoto in Kyoto, Japan

    Read More

  • Mar 04, 2024

    Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

    Leading the first clinical approval of an in vivo gene editing drug mediated by LNP in?China

    Read More

  • Feb 15, 2024

    Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies

    YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation

    Read More

XML 地图 | Sitemap 地图